Last $15.83 USD
Change Today +0.23 / 1.47%
Volume 304.0K
XNCR On Other Exchanges
Symbol
Exchange
Munich
As of 8:10 PM 03/2/15 All times are local (Market data is delayed by at least 15 minutes).

xencor inc (XNCR) Snapshot

Open
$15.70
Previous Close
$15.60
Day High
$15.86
Day Low
$15.10
52 Week High
01/29/15 - $19.50
52 Week Low
05/15/14 - $7.82
Market Cap
616.3M
Average Volume 10 Days
432.6K
EPS TTM
$-0.52
Shares Outstanding
38.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for XENCOR INC (XNCR)

Related News

No related news articles were found.

xencor inc (XNCR) Related Businessweek News

No Related Businessweek News Found

xencor inc (XNCR) Details

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing engineered monoclonal antibodies to treat severe and life-threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions through its proprietary XmAb technology platform. The company’s lead XmAb-engineered antibodies include XmAb5871, a B-cell inhibitor, which is in Phase Ib/IIa clinical trials for the treatment of autoimmune diseases, such as rheumatoid arthritis and lupus; XmAb7195, an IgE inhibitor under Phase Ib clinical trial initiation to treat asthma and allergic diseases; and XmAb5574/MOR208, a Cytotoxic B-cell depleting product candidate that is in Phase II clinical trials for the treatment of B-cell cancers. It has a collaboration agreement with Boehringer Ingelheim International GmbH; and development and manufacturing services agreement with Catalent Pharma Solutions LLC. The company was founded in 1997 and is based in Monrovia, California.

37 Employees
Last Reported Date: 02/23/15
Founded in 1997

xencor inc (XNCR) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $363.7K
Chief Medical Officer
Total Annual Compensation: $322.5K
Chief Business Officer
Total Annual Compensation: $290.0K
Compensation as of Fiscal Year 2013.

xencor inc (XNCR) Key Developments

Xencor, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Xencor, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported net loss of $1,350,000 compared to $3,703,000 a year ago. Revenues were $5,664,000 against $1,745,000 a year ago. Loss from operations was $1,350,000 against $3,710,000 a year ago. For the year, the company reported net loss of $16,422,000 compared to $60,259,000 a year ago. Fully diluted net loss per share was $0.52 compared to $3.85 a year ago. Revenues were $9,520,000 against $10,172,000 a year ago. Loss from operations was $16,457,000 against $10,520,000 a year ago.

Xencor, Inc. to Report Q4, 2014 Results on Feb 19, 2015

Xencor, Inc. announced that they will report Q4, 2014 results on Feb 19, 2015

Xencor, Inc., Q4 2014 Earnings Call, Feb 19, 2015

Xencor, Inc., Q4 2014 Earnings Call, Feb 19, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
XNCR:US $15.83 USD +0.23

XNCR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for XNCR.
View Industry Companies
 

Industry Analysis

XNCR

Industry Average

Valuation XNCR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 51.4x
Price/Book 8.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 58.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact XENCOR INC, please visit www.xencor.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.